Disparities Persist in Cancer Careers
Progress has been made through various government programs, but more work is needed.
Personalized Vaccine Induces Antitumor Activity
The neoantigen-specific immunotherapy elicited T-cell responses, complete and partial tumor responses.
Tiragolumab Impresses in Multiple Trials
The TIGIT inhibitor, alone and in combination with atezolizumab, showed efficacy against solid cancers.
Targeting CD19–CD22 Aids Younger Patients with ALL
A phase I trial of CAR therapy demonstrated possible benefit in blood cancer.
Tumors Appear Rife with Bacterial Lodgers
Microbes found living intracellularly in far more cancers than thought possible.
T Cells Targeting MAGE-A4 Shrink Tumors
Cells engineered to express T-cell receptor show early activity against sarcomas, other cancers.
AMG 510 Shows Activity beyond NSCLC
Partial responses, stable disease seen with first-in-class KRAS inhibitor in patients with various solid tumors.
Drug Designs Take Aim at OX40 Stimulation
Intratumoral injections of mRNA may succeed where agonist antibodies have failed.
Free Article | COVID-19 Delays Cancer Screenings
Temporarily postponing tests may not be problematic for patients, but it creates challenges for providers.
Proof-of-Concept with PROTACs in Prostate Cancer
ARV-110, which targets the AR for degradation, is safe and active in men with castration-resistant disease.
FDA Approves Selpercatinib; Pralsetinib May Soon Follow
Drugs target certain RET-altered lung and thyroid cancers, CNS metastases.
Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
As adjuvant therapy, tyrosine kinase inhibitor dramatically increases DFS, will likely change practice.
Trastuzumab Deruxtecan Impresses in Solid Cancers
Antibody–drug conjugate extends OS, PFS in gastric and GEJ tumors; elicits high ORRs in other malignancies.
PD-1 Inhibitor Bests Chemo for Colorectal Cancer
In patients with dMMR/MSI-H disease, first-line pembrolizumab doubles PFS, causes fewer toxicities.
Avelumab Outduels Supportive Care for Urothelial Cancer
As a maintenance therapy, PD-L1 inhibitor extends OS, PFS.
Olaparib Makes OS Gains in Ovarian Cancer
The PARP inhibitor solidified its place as a standard maintenance therapy for relapsed, BRCA-mutant disease.
Free Article | Registries Offer Insights on COVID-19–Cancer Connection
Two large-scale efforts reveal a high mortality rate, highlight risk factors.